Summary

Location
at UCLA
Dates
study started
estimated completion
Principal Investigator
by Jaime DeVille (ucla)

Description

Summary

The purpose of this study is to measure how well LY3819253 and LY3832479 work against the virus that causes COVID-19. LY3819253 and LY3832479 will be given to participants with early symptoms of COVID-19. Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study. Participation could last about 12 weeks and includes one required visit to the study site, with the remainder of assessments performed in the home or by phone.

Official Title

A Randomized, Double-blind, Placebo-Controlled, Phase 2/3 Study to Evaluate the Efficacy and Safety of LY3819253 and LY3832479 in Participants With Mild to Moderate COVID-19 Illness

Keywords

COVID-19

Eligibility

You can join if…

  • Are currently not hospitalized. (Not applicable to participants in treatment arm 22.)
  • Have one or more mild or moderate COVID-19 symptoms: Fever, cough, sore throat, malaise, headache, muscle pain, gastrointestinal symptoms, or shortness of breath with exertion. (Not applicable to participants in treatment arm 22.)
  • Must have sample taken for test confirming viral infection no more than 3 days prior to starting the drug infusion
  • Are males or females, including pregnant females who agree to contraceptive requirements
  • Understand and agree to comply with planned study procedures
  • Agree to the collection of nasopharyngeal swabs and venous blood. (Not applicable to participants in treatment arms 20-21.)
  • The participant or legally authorized representative give signed informed consent and/or assent

Participants in treatment arms 7-9, 13-14, and 18-21 ONLY

  • Are greater than or equal to (≥)18 years of age and must satisfy at least one of the following at the time of screening
  • Are pregnant
  • Are ≥65 years of age
  • Have a body mass index (BMI) ≥35
  • Have chronic kidney disease (CKD)
  • Have type 1 or type 2 diabetes
  • Have immunosuppressive disease
  • Are currently receiving immunosuppressive treatment or
  • Are ≥55 years of age AND have:
  • cardiovascular disease (CVD), OR
  • hypertension, OR
  • chronic obstructive pulmonary disease (COPD) or other chronic respiratory disease
  • Are 12-17 years of age (inclusive) AND satisfy at least one of the following at the time of screening
  • Are pregnant
  • Have a body mass index (BMI) ≥85th percentile for their age and gender based on

CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm

  • Have sickle cell disease
  • Have congenital or acquired heart disease
  • Have neurodevelopmental disorders, for example, cerebral palsy
  • Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
  • Have asthma or reactive airway or other chronic respiratory disease that requires daily medication for control
  • Have type 1 or type 2 diabetes
  • Have chronic kidney disease
  • Have immunosuppressive disease, or
  • Are currently receiving immunosuppressive treatment

Participants in treatment arm 22 ONLY

  • Are 0 (≥ 32 weeks gestational age AND ≥ 1.5 kilograms [kg]) to 17 years of age (inclusive) AND satisfy at least one of the following risk factors at the time of screening
  • Are pregnant
  • Have a BMI ≥85th percentile for their age and gender based on CDC growth charts, https://www.cdc.gov/growthcharts/clinical_charts.htm
  • Have sickle cell disease
  • Have congenital or acquired heart disease
  • Have neurodevelopmental disorders, for example, cerebral palsy, autism, or Down syndrome (FAIR Health 2020; Spreat et al. 2020)
  • Have a medical-related technological dependence, for example, tracheostomy, gastrostomy, or positive pressure ventilation (not related to COVID-19)
  • Have asthma, cystic fibrosis, reactive airways disease or other chronic respiratory disease that requires daily medication for control
  • Have type 1 or type 2 diabetes
  • Have chronic kidney disease
  • Have immunosuppressive disease, or
  • Are currently receiving immunosuppressive treatment, or
  • Are less than (<) one year of age.
  • Have one or more COVID-19 symptoms
  • Shortness of breath/difficulty breathing
  • Fever
  • Sore throat
  • Nausea
  • Diarrhea
  • Tiredness
  • Headache
  • New loss of taste
  • Nasal congestion/runny nose
  • Chills
  • Stomachache
  • Vomiting
  • Cough
  • Muscle/body aches and pain
  • New loss of smell
  • Poor appetite or poor feeding (in babies)

You CAN'T join if...

  • Have oxygen saturation (SpO2) less than or equal to (≤)93 percent (%) on room air at sea level or ratio of arterial oxygen partial pressure (PaO2 in millimeters of mercury) to fractional inspired oxygen (FiO2) less than (<)300, respiratory rate greater than or equal to (≥)30 per minute, heart rate ≥125 per minute due to COVID-19
  • Require mechanical ventilation or anticipated impending need for mechanical ventilation due to COVID-19
  • Have known allergies to any of the components used in the formulation of the interventions
  • Have hemodynamic instability requiring use of pressors within 24 hours of randomization
  • Suspected or proven serious, active bacterial, fungal, viral, or other infection (besides COVID-19) that in the opinion of the investigator could constitute a risk when taking intervention
  • Have any co-morbidity requiring surgery within <7 days, or that is considered life-threatening within 29 days
  • Have any serious concomitant systemic disease, condition or disorder that, in the opinion of the investigator, should preclude participation in this study
  • Have a history of a positive SARS-CoV-2 test prior to the one serving as eligibility for this study
  • Have received an investigational intervention for SARS-CoV-2 prophylaxis within 30 days before dosing
  • Have received treatment with a SARS-CoV-2 specific monoclonal antibody
  • Have received convalescent COVID-19 plasma treatment
  • Have participated, within the last 30 days, in a clinical study involving an investigational intervention. If the previous investigational intervention has a long half-life, 5 half-lives or 30 days, whichever is longer, should have passed
  • Are concurrently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study
  • Mothers who are breast feeding

Participants in Treatment Arm 22 ONLY

  • Have a diagnosis of Multisystem Inflammatory Syndrome in Children (MIS-C) in the opinion of the investigator
  • Are currently hospitalized for treatment of COVID-19. Other reasons for hospitalization are acceptable.

Locations

  • UCLA Mattel Children's Hospital not yet accepting patients
    Los Angeles California 90095 United States
  • Cedars Sinai Medical Center accepting new patients
    Los Angeles California 90048-5615 United States
  • Kaiser Permanente - SD Med Ctr completed
    San Diego California 92123 United States
  • Wolverine Clinical Trials, LLC accepting new patients
    Santa Ana California 92705 United States

Lead Scientist at University of California Health

  • Jaime DeVille (ucla)
    HS Clinical Professor, Pediatrics. Authored (or co-authored) 19 research publications.

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Eli Lilly and Company
Links
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness (BLAZE-1)
ID
NCT04427501
Phase
Phase 2/3
Study Type
Interventional
Last Updated